Paris, France; Cambridge, Massachusetts (USA); October 20, 2021 – NANOBIOTIX (Euronext: NANO –
NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced operational progress and cash position (unaudited) for the third quarter of 2021.
Third Quarter Financial Updates
Nanobiotix reported cash, cash equivalents, and short-term investments totaling €89.8 million as of September 30, 2021, compared to €119.2M as of December 31, 2020.
Third Quarter Operational Highlights and Upcoming Milestones
 It being specified that the company did not generate any revenue during the third quarter of 2021, this following the termination of the PharmaEngine partnership.